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Aims An estimated 10 000–15 000 pacemaker and implantable cardioverter–deﬁbrillator (ICD) leads are extracted
annually worldwide using specialized tools that disrupt encapsulating ﬁbrous tissue. Additional information is
needed regarding the safety of the devices that have been approved for lead extraction. The aim of this study was
to determine whether complications due to device-assisted lead extraction might be more hazardous than published
data suggest, and whether procedural safety precautions are effective.
Methods
and results
We searched the US Food and Drug Administration’s (FDA) Manufacturers and User Deﬁned Experience (MAUDE)
database from 1995 to 2008 using the search terms ‘lead extraction and death’ and ‘lead extraction and injury’.
Additional product speciﬁc searches were performed for the terms ‘death’ and ‘injury’. Between 1995 and 2008, 57
deaths and 48 serious cardiovascular injuries associated with device-assisted lead extraction were reported to the
FDA. Owing to underreporting, the FDA database does not contain all adverse events that occurred during this
period. Of the 105 events, 27 deaths and 13 injuries occurred in 2007–2008. During these 2 years, 23 deaths were
linked with excimer laser or mechanical dilator sheath extractions. The majority of deaths and injuries involved ICD
leads, and most were caused by lacerations of the right atrium, superior vena cava, or innominate vein. Overall, 62
patientsunderwentemergencysurgicalrepairofmyocardialperforationsandvenouslacerationsand35(56%)survived.
Conclusion These ﬁndings suggest that device-assisted lead extraction is a high-risk procedure and that serious complications
including death may not be mitigated by emergency surgery. However, skilled standby cardiothoracic surgery is essen-
tial when performing pacemaker and ICD lead extractions. Although the incidence of these complications is
unknown, the results of our study imply that device-assisted lead extractions should be performed by highly qualiﬁed
physicians and their teams in specialized centres.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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An estimated 10 000–15 000 pacemaker and implantable cardio-
verter–deﬁbrillator (ICD) leads are extracted annually worldwide
using specialized tools and techniques (personal communication
with physicians and industry). These device-assisted procedures
employ technologies that free leads from encapsulating ﬁbrous
tissue which binds them to major veins and cardiac structures
and other implanted leads.
1–6 Although infection has been the
most common indication for device-assisted lead extraction, lead
malfunction, the removal of abandoned and recalled leads, and
the need to ‘upgrade’ existing systems to deﬁbrillation or cardiac
resynchronization devices have increased the number of extrac-
tions performed in recent years. The requirement to completely
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extraction tools that can ablate or disrupt ﬁbrous tissue. Such
devices use laser
3 and radiofrequency (RF)
4 energy and novel
cutting sheaths
6 that have increased the proportion of leads com-
pletely removed compared with countertraction using non-
powered or specialized sheaths. However, it is known that lead
extraction with or without device assistance is a procedure that
may be complicated by death, haemopericardium, and other life-
threatening injuries.
1–3
The controversy surrounding the management of patients who
have Sprint Fidelis ICD leads
7 and the report of deaths associated
with Sprint Fidelis lead extraction
8 prompted us to examine the
worldwide adverse events that have been reported by manufac-
turers, hospitals, and health providers to the US Food and Drug
Administration (FDA). The aim of this study was to determine
whether complications due to device-assisted lead extraction
might be more hazardous than available data suggest, and
whether procedural safety precautions, including standby cardi-
othoracic surgery, are effective.
Methods
United States Food and Drug Administration
manufacturers and user-deﬁned experience
database
The FDA’s Manufacturers and User Deﬁned Experience (MAUDE)
database contains reports of adverse events involving medical
devices worldwide. The majority of reports originate from device
manufacturers; 5–7% are submitted by user facilities, including
hospitals and clinics.
9–11The FDA has required device manufacturers
to report adverse events that are communicated to them since
1995. Adverse events are ﬁled as Medical Device Reports (MDRs),
which are searchable online at www.fda.gov/cdrh/maude.html. The
relevant data items for an MDR are: (i) device type and model, (ii)
report source (e.g. hospital or manufacturer), (iii) event date and
location, (iv) device age, (v) patient outcome, (vi) a narrative of the
event, and (vii) the manufacturers evaluation of returned devices if
available.
For this study, simple searches were conducted for the terms ‘lead
extraction and death’ and ‘lead extraction and injury’; additional
advanced manufacturer- and product-speciﬁc searches were per-
formed for the search terms ‘death’ and ‘injury’. The searches were
conducted in March 2009. These searches produced 123 MDRs that
satisﬁed the search criteria. Although each MDR had a unique numeri-
cal identiﬁer, 16 MDRs were clearly duplicate reports of the same
events that were either submitted by a different party or were erro-
neously resubmitted by the manufacturer or user facility. Two MDRs
described laser generator failure during lead extraction, which resulted
in uncomplicated lead extraction by thoracotomy. After excluding the
duplicate reports and the laser generator failures, we analysed 105
MDRs that reported deaths and injuries associated with device-assisted
lead extraction.
Techniques and devices
The term ‘lead extraction’ applies to pacemaker and ICD leads that
have been implanted .1 year or that require special equipment to
remove regardless of implant age.
12 Lead removals via an access
other than the original venous insertion site are also considered
extractions. Pacemaker and ICD lead extraction is initially attempted
by inserting a regular stylet to preserve the lead’s lumen, disengaging
the active ﬁxation mechanism if possible, and applying steady traction
with or without the use of a specialized locking stylet that stabilizes the
lead. Many leads—particularly those implanted ,3–4 years—can be
removed by this basic countertraction method. If traction alone is
unsuccessful, physicians may use one or several lead extraction
devices as described in the following. Locking stylets are routinely
used with these extraction devices. Leads that fracture or otherwise
cannot be removed from the primary venous insertion site, e.g. cepha-
lic or subclavian vein, may require extraction via the femoral vein using
a variety of extraction tools such as snares. Surgical removal by thor-
acotomy is usually reserved for failed extractions and for infected leads
with large vegetations. A successful extraction is complete lead
removal, whereas a failed extraction has been deﬁned as leaving
.4 cm of lead in situ.
Excimer laser sheath
The excimer laser sheath (SLS II, Spectranetics Inc., Colorado Springs,
CO, USA) contains optical ﬁbres that are arranged circumferentially
between inner and outer polymer tubing.
13 The optical ﬁbres termi-
nate in the distal tip where they produce a circle of pulsed eximer
laser light consisting of high-energy short-duration pulses (135 ns) at
low temperature (508C) and shallow tissue penetration
(100 mm). The resultant photoablation of non-calciﬁed ﬁbrous
tissue yields water, gas, and small particles (90% ,90 mm). During
use, the laser sheath is placed in a 42 cm outer sheath that is cut at
a4 5 8 at one end with bevelled edges; this outer sheath is used to intro-
duce and align the laser sheath and to serve as a conduit for removing
the extracted lead. Some operators prefer not to use the outer sheath.
The excimer laser generator interfaces with the laser sheath via a
modular connector that delivers ultraviolet energy to the optical
ﬁbres. The manufacturer’s labelling speciﬁes that its excimer laser pro-
ducts should not be used unless the procedure room is prepared for
emergency thoracotomy or pericardiocentesis, that surgical back-up is
arranged, and that the patient be prepped for thoracotomy with
packed red blood cells immediately available for transfusion.
13 Laser-
assisted lead extraction
14 (Figure 1) is performed under ﬂuoroscopic
control by (i) selecting a 12, 14, or 16 French laser sheath depending
on the diameter of the lead to be removed; (ii) advancing the laser
sheath and optional outer sheath over the lead and activating the
laser as ﬁbrous tissue is encountered; (iii) dislodging the lead tip by
countertraction and removing the lead. Safety precautions include
maintaining a coaxial orientation of the laser sheath to the lead and
keeping the outer sheath’s long bevel from contacting the superior
vena cava.
Mechanical dilator sheath
The EvolutionTM mechanical dilator sheath (Cook Vascular Inc., Van-
dergrift, PA, USA) is a rotationally powered telescoping device with
an inner sheath that has a stainless steel bladed distal tip.
15 The
sheath is connected to a manually operated tool that rotates the
bladed inner sheath so that ﬁbrous tissue is disrupted as the sheath
is advanced over the course of the lead.
5,6
Electrosurgical dissection sheath
This specialized sheath (PerfectaTM, Cook Vascular Inc.) delivers RF
energy via tungsten bipolar electrodes contained in the tip of a
Teﬂon sheath set that is advanced over the lead inside an outer
sheath.
16 Fibrous tissue is ablated or dissected using a standard RF gen-
erator (Valleylab Force FXTM, Valleylab, Boulder, CO, USA) that deli-
vers 25 watts pulsed at 80 cycles per minute under operator control.
4
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similar to those used with other extraction sheaths.
Polypropylene or Teﬂon dilator sheath
The polypropylene or Teﬂon dilator sheath (Byrd, Cook Vascular Inc.)
has been available for two decades. It is a telescoping sheath that
ranges in size from 7 to 13 French and it is used in conjunction with
a locking stylet that allows the operator to maintain traction on the
lead while the sheath is advanced over the lead.
17 As is true for all
sheath-based techniques, keys to safety and successful removal
include meticulous preparation of the lead and maintaining coaxial
alignment of the sheath with the lead.
5
Results
Between 1995 and 2008, 57 peri-operative deaths and 48 serious
procedural injuries associated with device-assisted lead extraction
were reported to the FDA (Table 1); approximately a third of
reports originated outside the USA. These 105 events involved
the extraction of one or more pacemaker leads (n ¼ 34), ICD
leads (n ¼ 42), pacemaker and ICD leads (n ¼ 6), and unspeciﬁed
leads (n ¼ 23). The most frequently reported indication for extrac-
tion was lead malfunction, including 10 leads that had been subject
to advisories by their manufacturers. Of the 105 events, 27 deaths
and 13 injuries occurred in 2007–2008. During these 2 years, 23
deaths were linked to excimer laser or mechanical dilator sheath
extractions. Overall, 62 patients underwent emergency surgical
repair of myocardial perforations and venous lacerations and 35
(56%) survived.
Excimer laser extraction
The MAUDE data for 25 patients who died and 20 patients who
sustained life-threatening injuries as the result of laser-assisted
lead extraction are summarized in Table 2. The majority of
deaths and injuries involved ICD leads and most were caused by
lacerations of the right atrium, superior vena cava, or innominate
vein (n ¼ 31; 70%). Of the 34 patients who underwent emergency
thoracotomy or sternotomy to repair venous lacerations or myo-
cardial perforations, 17 (50%) died during or after surgery.
.....................
................................................................................
Table 1 Lead extraction devices associated with
reported deaths and serious injuries in the FDA
MAUDE database1995–2008
Lead extraction device n Number of
events
Death Injury
Excimer laser sheath 45 25 20
Mechanical dilator sheath 8 6 2
Electrosurgical dissection sheath 2 2 0
Polypropylene or Teﬂon dilator sheath 24 6 18
Unspeciﬁed extraction devices 26 18 8
Total 105 57 48
Owing to underreporting, all events that actually occurred during this timeframe
are not in the FDA database, and hence are not represented in the table.
Figure 1 Laser-assisted lead extraction. The excimer laser sheath is advanced over the lead and photoablates the ﬁbrous tissue that binds the
lead to the superior vena cava.
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Table 2 Deaths and serious injuries associated with excimer laser and mechanical dilator sheath-assisted lead
extractions
Patient no./MDR
Event Key
a
Outcome Lead types Lead age Indication Complication Intervention
Excimer laser sheath
1/154622 Death PM 9 months Unspeciﬁed SVC–RA laceration Surgery
b
2/234845 Death ICD NS Lead malfunction SVC–RA–innominate laceration Surgery
3/314515 Death ICD NS Unspeciﬁed Unspeciﬁed Unspeciﬁed
4/374708 Death PM NS Unspeciﬁed SVC–innominate laceration Surgery
Leads
5/630627 Death PM 4 years Lead malfunction SVC laceration Unspeciﬁed
6/547246 Death ICD Chronic Infection SVC laceration Surgery
PM
7/967415 Death PM NS Unspeciﬁed Innominate vein tear Surgery
Leads
8/893139 Death ICD 10 years Lead malfunction SVC laceration Expired before surgery initiated
9/893137 Death ICD 10 years Lead malfunction SVC–RA laceration Surgery
10/910339 Death ICD NS Unspeciﬁed SVC laceration Surgery
PM
11/958449 Death ICD 5 years Infection SVC–RA laceration Surgery
PM
12/946850 Death PM NS Upgrade to CRT SVC laceration Surgery
13/973499 Death ICD .10 years Unspeciﬁed Hypotension Unspeciﬁed
14/989544 Death ICD 2.5 years Lead malfunction Hypotension Unspeciﬁed
15/1007232 Death ICD 5 years Infection SVC laceration Surgery
16/1019345 Death NS NS Lead malfunction Hypotension Unspeciﬁed
17/1046068 Death ICD Chronic Lead malfunction SVC transsection Surgery
18/1071466 Death ICD 7 years Infection SVC laceration Surgery
19/1046069 Death ICD 5 years Lead malfunction Haemopericardium Surgery
20/071467 Death PM 8 years Upgrade to ICD SVC laceration Surgery
Multiple
21/1074798 Death ICD NS Lead malfunction Unspeciﬁed Unspeciﬁed
22/1198584 Death NS NS Infection SVC laceration Surgery
23/1248243 Death ICD NS Infection SVC laceration Surgery
24/1213923 Death PM 16 years Unspeciﬁed RV perforation Surgery
A and V
25/106917 Death ICD Chronic Infection Pulmonary embolus None
26/44954 Injury PM 4 years Unspeciﬁed Right atrial tear Surgery
Survived
27/264781 Injury ICD 4 years Lead malfunction SVC damage Surgery
Survived
28/684296 Injury ICD NS Lead malfunction SVC laceration Unspeciﬁed
Survived
29/273728 Injury NS NS Unspeciﬁed Haemopericardium Surgery
Survived
30/684495 Injury ICD 5 years Lead malfunction Haemopericardium Surgery
Survived
31/637729 Injury ICD NS Unspeciﬁed Haemothorax Surgery
Survived
32/543895 Injury ICD 7 years Lead malfunction Right atrial tear Surgery
Survived
33/544293 Injury ICD 6 years Lead malfunction SVC laceration Surgery
Survived
34/605731 Injury ICD NS Infection SVC laceration Surgery
Survived PM
Continued
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Six peri-operative deaths were associated with the EvolutionTM
mechanical dilator sheath extraction, and the manufacturer
reported all of them in 2008 (Table 2). Two deaths were caused
by superior vena cava lacerations, one as the result of a right
atrial tear, and three were due to ‘haemorrhage’. Three of the
six deaths involved ICD leads that were being extracted for unspe-
ciﬁed reasons. Two ICD patients survived innominate vein tears
that were successfully treated surgically.
Electrosurgical dissection sheath
The manufacturer reported two deaths that were related to the
use of a PerfectaTM electrosurgical dissection sheath to extract
pacemaker leads, one of which had been implanted for 18 years.
One death was due to haemopericardium, and the second
patient died of unspeciﬁed reasons during the procedure.
Polypropylene or Teﬂon dilator sheaths
Between 1996 and 2000, the manufacturer reported 23 adverse
events associated with this product, which was used during the
extraction of 9 pacemaker leads, 1 ICD lead, and 13 unspeciﬁed
leads. Our search found no further MDRs for Cook polypropylene
or Teﬂon dilator sheaths from 2000 to 2008, when a single injury
report was posted on MAUDE for an unspeciﬁed lead extraction.
The 24 events associated with this extraction tool included 6
deaths and 18 injuries that were caused by subclavian, innominate,
...............................................................................................................................................................................
Table 2 Continued
Patient no./MDR
Event Key
a
Outcome Lead types Lead age Indication Complication Intervention
35/674412 Injury ICD 9 years Lead malfunction Haemopericardium Unspeciﬁed
Survived
36/785931 Injury NS NS Lead malfunction Innominate vein tear Surgery
Survived
37/930464 Injury NS 10 years Unspeciﬁed SVC laceration Surgery
Survived
38/930837 Injury NS 8 years Infection SVC laceration Surgery
Survived Multiple
39/958245 Injury PM 14 years Lead malfunction Right atrial tear Surgery
Survived A and V
40/1007205 Injury ICD 4 years Unspeciﬁed Haemopericardium Surgery
Survived PM
41/1019437 Injury ICD 2 years Lead malfunction SVC laceration Surgery
Survived
42/1046003 Injury ICD NS Infection SVC–RA laceration Surgery
Survived
43/1227551 Injury NS NS Unspeciﬁed SVC laceration Surgery
Survived
44/1227550 Injury ICD NS Infection SC artery laceration Surgery
Survived
45/1272964 Injury NS NS Unspeciﬁed SVC laceration Surgery
Survived
Mechanical dilator sheath
46/1185004 Death ICD NS Unspeciﬁed Right atrial tear Surgery
47/1032536 Death ICD NS Unspeciﬁed Haemorrhage Chest tube
48/1185003 Death ICD NS Unspeciﬁed Haemorrhage Surgery
PM
49/1206484 Death NS NS Unspeciﬁed SVC laceration Surgery
50/1222585 Death PM 4 years Unspeciﬁed SVC laceration Surgery
Multiple
51/1273598 Death PM NS Lead malfunction Haemopericardium Surgery
A and V
52/978823 Injury PM NS Infection Innominate vein tear Unspeciﬁed
Survived Multiple
53/1264795 Injury ICD 3 years Lead malfunction Innominate vein tear Surgery
Survived
ICD, implantable cardioverter–deﬁbrillator; PM, pacemaker; NS, not speciﬁed; SVC, superior vena cava; RV, right ventricle; SC, subclavian; A, atrial lead; V, ventricular lead.
aMDR, Medical Device Report. The MDR may be accessed at www.fda.gov/cdrh/maude.html by entering the MDR Event Key number into the simple search ﬁeld.
bSurgery indicates thoracotomy or sternotomy.
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(n ¼ 7), haemothorax (n ¼ 2), lead entrapment in the sheath
(n ¼ 2), pneumothorax (n ¼ 1), and embolic cerebrovascular
accident (n ¼ 1). Of the 16 patients whose intervention was
recorded, 11 underwent surgery including 2 patients who died
peri-operatively.
Unspeciﬁed extraction devices
Between 1995 and 2008, 26 MDRs were submitted by three pace-
maker and ICD manufacturers and three health professionals
describing 18 deaths and 8 injuries that occurred during an extrac-
tion procedure involving one of the manufacturer’s products or at
the health professional’s facility. These events involved 15 ICD and
11 pacemaker leads that were being removed for malfunction (n ¼
19), infection (n ¼ 3), prophylactically due to manufacturers’ advi-
sory (n ¼ 2), and unspeciﬁed reasons (n ¼ 2). The 18 deaths were
caused by superior vena cava lacerations (n ¼ 5; 27%), haemor-
rhage (6; 33%), haemopericardium (n ¼ 2; 11%), respiratory
arrest (n ¼ 1; 6%), and unspeciﬁed causes (n ¼ 4; 22%). Of the
10 patients who underwent immediate thoracotomy or sternot-
omy, 8 survived, including one who required tricuspid valve repair.
Discussion
This study shows that device-assisted lead extraction has resulted
in fatal cardiovascular injuries often despite emergency surgical
intervention. Moreover, the majority of the reported deaths have
occurred in the last 2 years, and most of them were caused by
lacerations of major veins during laser or mechanical dilator
sheath extractions. This ﬁnding is timely and important because
more than 100 000 patients have underperforming Sprint Fidelis
ICD leads that may require replacement. Medtronic has announced
that 4 of the 13 deaths due to fractures of Sprint Fidelis leads were
associated with the extraction of the failed lead.
8 Medtronic’s
medical advisors have recommended that only physicians who
have ‘extensive’ extraction experience should remove Sprint
Fidelis leads. The results of our study and the known inverse
relationship between extraction experience and procedural com-
plications
1,2,12,18,19 support this recommendation.
Byrd
20 reported the ﬁrst excimer laser-assisted pacemaker lead
extraction in 1996. The multicentre randomized pacing lead
extraction with the excimer sheath (PLEXES) trial found that laser-
assisted extraction was more efﬁcacious than non-laser techniques
in 301 patients.
3 Laser-assisted extraction resulted in a signiﬁcantly
higher proportion of complete lead removals than non-laser
methods (94 vs. 64%; P , 0.001). However, even though there
was no statistically signiﬁcant difference in life-threatening compli-
cations between the laser and non-laser groups (P ¼ 0.28), one
death due to a right atrial laceration and three other major com-
plications in the laser group prompted the investigators to con-
clude that laser-assisted pacemaker lead extraction was
associated with signiﬁcant risks. A subsequent non-randomized
European multicentre study of excimer laser-assisted pacemaker
and ICD lead extractions in 292 patients reported a 5.1% compli-
cation rate, including 10 non-fatal vascular and cardiac
perforations.
21
Nevertheless, excimer laser-assisted lead extraction has been
successful and reasonably safe in large single-centre experiences.
Jones et al.
22 recently reported their centre’s results for 975 pace-
maker and ICD lead extractions in 498 patients over a 7-year
period. Although the excimer laser was used for 77.6% of the
leads, there were just two cases of tamponade and no procedural
deaths. Importantly, 97.5% of leads were completely removed.
Another single-centre study included laser-assisted extraction of
619 pacemaker and ICD leads that had been implanted for an
average of 7.6 years with no device-related mortality.
23 During
the extraction of 277 pacemaker leads by Roux et al.,
24 the only
death occurred when laser extraction was attempted on both
left- and right-sided leads. A single-centre’s retrospective study
reported one fatality during laser-assisted extraction of 91 ICD
leads; this death was caused by a superior vena cava–right atrial
tear despite immediate thoracotomy.
25
Byrd
26 and Schaerf et al.
27 have reported their experiences with
the mechanical dilator sheath that included182 pacemaker and ICD
leads which were removed by them without a death. Our study is
the ﬁrst to report major adverse events related to lead extraction
with this device.
A multicentre historically controlled study of the electrosurgical
dissection sheath reported six major adverse events in 166 patients
(3.6%), including one death due to a superior vena cava tear and
ﬁve cases of haemopericardium and haemothorax.
16 A 160
patient randomized study of electrosurgical dissection sheaths
found them to be more effective than standard counter-traction
techniques, and the only complication was pacemaker pocket
haemorrhage requiring transfusion in three patients.
4
It is apparent from our study that emergency surgical interven-
tion to rescue patients who have suffered a venous laceration or
myocardial tear may be unsuccessful even when all appropriate
pre-procedure precautions have been taken. However, it is also
clear that immediate surgical intervention was successful in many
patients (Table 2), and hence competent cardiothoracic surgical
standby is essential when performing pacemaker and ICD lead
extractions. Still, it is vital that these injuries be avoided. As indi-
cated by the MAUDE data and multiple studies,
19,24,25 the innomi-
nate vein–superior vena cava–high right atrium is a region of great
risk for fatal extraction injuries. Local tissue factors, such as calci-
ﬁcation and infection, or the presence of other leads may confound
the best available techniques, and operators must know when to
stop the extraction and use a different approach such as another
tool, surgery, or simply abandoning the lead.
5,28
Studies have shown that the risks of device-assisted lead extrac-
tion increase with the age and type of lead, presence of calciﬁca-
tion around the lead, female patients, and the experience of the
physician performing the procedure.
1,2,19,22 Only the latter is a
controllable risk factor, but a recent survey of Heart Rhythm
Society members found that just 18% of physicians perform
more than 50 extractions a year, and 25% of extraction procedures
are done without a surgeon or operating room on standby.
29 The
Heart Rhythm Society’s recent expert consensus panel empha-
sized that the steepest decline in lead extraction complication
rates occurs during the operator’s ﬁrst 30 cases and that the
decline continues up to 400 cases.
12 The expert consensus panel
also noted that an experienced physician’s success rate with
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than 15 procedures per year.
This study has certain implications for research and develop-
ment, physician training and credentialing,
30 and the regulation of
medical devices. Prospective studies are needed to determine
the risks and beneﬁts of extracting rather than abandoning non-
infected leads.
31 Regulatory agencies should consider limiting the
sale of extraction devices to qualiﬁed physicians and institutions.
Hospitals should apply strict criteria, such as those speciﬁed by
the Heart Rhythm Society,
12 for credentialing physicians who
wish to perform device-assisted lead extraction.
Our study has certain limitations. Owing to underreporting, the
MAUDE database does not contain all major adverse events invol-
ving lead extraction devices that occurred during the period of the
study. Disparities may exist because events are not reported to the
manufacturer, and users infrequently report deaths or serious inju-
ries that occur at their facilities. Moreover, manufacturers may
report adverse events to the FDA in annual product reports,
which are generally unavailable to the public. For example, no
MDRs exist for Teﬂon sheaths from 2000 to 2008 even though
it is highly likely that adverse events with this sheath did occur
during this period. Owing to these and possibly other limitations,
no conclusion should be drawn regarding the incidence of
device-assisted lead extraction deaths and cardiovascular injuries
or the relative safety of the various extraction devices. Further, it
is possible that more than one extraction device was used during
some of the procedures.
In conclusion, device-assisted chronic pacemaker and ICD lead
extractions have resulted in deaths and cardiovascular injuries
due to catastrophic venous tears and myocardial perforations.
Many of the deaths occurred despite emergency surgical interven-
tion. However, immediate surgery was often successful, and com-
petent standby cardiothoracic surgery is essential when performing
pacemaker and ICD lead extraction with or without device assist-
ance. The number of adverse events in the FDA MAUDE database
underestimates the actual number of major complications associ-
ated with device-assisted lead extraction. These ﬁndings suggest
that device-assisted lead extraction should be performed only in
specialized centres by highly experienced physicians and their
teams.
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